IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
Relative valuation derived from Materials sector median benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Multiples adjusted for extreme outliers and non-recurring volatility.
Auditing capital efficiency...
Quality Profile Audit
Score: 50GRADE C+
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation.
Return on Equity
Profit generated per dollar of shareholder equity
11.9%
Sector: 3.3%
Dividend Analysis audit
No Dividend
This company does not currently pay a dividend.
Analyst Projections
Analyst Consensus
Unlock Valuation Tools
Sign up for free access to institutional-quality research tools.
Based on our 6-factor quantitative model, BALCHEM CORP (BCPC) receives a "Hold" rating with a composite score of 50.2/100, ranked #1077 out of 4446 stocks. Key factor scores: Quality 50/100, Value 55/100, Momentum 51/100. This is quantitative analysis only — not investment advice.
BALCHEM CORP (BCPC) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does BALCHEM CORP Do?
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets in the United States and internationally. It operates through three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates. This segment also offers microencapsulation solutions for various applications; and human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. The Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production, and delivering nutrient supplements in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; and choline chloride, a nutrient for monogastric animal health. The Specialty Products segment offers ethylene oxide primarily for use in the health care industry; and single use canisters with ethylene oxide for sterilizing re-usable devices. This segment also markets and sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. The company sells its products through sales force, independent distributors, and sales agents. Balchem Corporation was incorporated in 1967 and is headquartered in New Hampton, New York. BALCHEM CORP (BCPC) is classified as a mid-cap stock in the Materials sector, specifically within the Chemicals industry. The company is led by CEO Theodore L. Harris and employs approximately 1,340 people, headquartered in NEW HAMPTON, New Jersey. With a market capitalization of $5.5B, BCPC is one of the notable companies in the Materials sector.
BALCHEM CORP (BCPC) Stock Rating — Hold (April 2026)
As of April 2026, BALCHEM CORP receives a Hold rating with a composite score of 50.2/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.BCPC ranks #1,077 out of 4,446 stocks in our coverage universe. Within the Materials sector, BALCHEM CORP ranks #67 of 284 stocks, placing it in the top quartile of its Materials peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
BCPC Stock Price and 52-Week Range
BALCHEM CORP (BCPC) currently trades at $174.93. The stock lost $0.14 (0.1%) in the most recent trading session. The 52-week high for BCPC is $183.51, which means the stock is currently trading -4.7% from its annual peak. The 52-week low is $139.17, putting the stock 25.7% above its annual trough. Recent trading volume was 127K shares, suggesting relatively thin trading activity.
Is BCPC Overvalued or Undervalued? — Valuation Analysis
BALCHEM CORP (BCPC) carries a value factor score of 55/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 37.30x, compared to the Materials sector average of 26.50x — a premium of 41%. The price-to-book ratio stands at 4.43x, versus the sector average of 2.83x. The price-to-sales ratio is 5.50x, compared to 0.74x for the average Materials stock. On an enterprise value basis, BCPC trades at 27.19x EV/EBITDA, versus 6.01x for the sector.
Overall, BCPC's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.
BALCHEM CORP Profitability — ROE, Margins, and Quality Score
BALCHEM CORP (BCPC) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 11.9%, compared to the Materials sector average of 3.3%, which is within a healthy range. Return on assets (ROA) comes in at 8.9% versus the sector average of 0.6%.
On a margin basis, BALCHEM CORP reports gross margins of 35.7%, compared to 29.8% for the sector. The operating margin is 20.2% (sector: 6.0%). Net profit margin stands at 14.7%, versus 3.0% for the average Materials stock. Revenue growth is running at 14.3% on a trailing basis, compared to 1.8% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.
BCPC Debt, Balance Sheet, and Financial Health
BALCHEM CORP has a debt-to-equity ratio of 34.0%, compared to the Materials sector average of 41.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 2.07x, indicating strong short-term liquidity. Cash and equivalents stand at $65M.
BCPC has a beta of 0.67, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for BALCHEM CORP is 88/100, indicating low-volatility characteristics and consistent price behavior that appeals to risk-averse investors.
BALCHEM CORP Revenue and Earnings History — Quarterly Trend
In TTM 2026, BALCHEM CORP reported revenue of $1.01B and earnings per share (EPS) of $4.80. Net income for the quarter was $149M. Gross margin was 35.7%. Operating income came in at $205M.
In FY 2025, BALCHEM CORP reported revenue of $1.04B and earnings per share (EPS) of $4.80. Net income for the quarter was $155M. Gross margin was 35.7%. Revenue grew 8.8% year-over-year compared to FY 2024. Operating income came in at $209M.
In Q3 2025, BALCHEM CORP reported revenue of $268M and earnings per share (EPS) of $1.25. Net income for the quarter was $40M. Gross margin was 35.7%. Revenue grew 11.5% year-over-year compared to Q3 2024. Operating income came in at $55M.
In Q2 2025, BALCHEM CORP reported revenue of $255M and earnings per share (EPS) of $1.18. Net income for the quarter was $38M. Gross margin was 36.4%. Revenue grew 9.1% year-over-year compared to Q2 2024. Operating income came in at $51M.
Over the past 8 quarters, BALCHEM CORP has demonstrated a growth trajectory, with revenue expanding from $234M to $1.01B. Investors analyzing BCPC stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
BCPC Dividend Yield and Income Analysis
BALCHEM CORP (BCPC) does not currently pay a dividend. This is common among smaller companies in the Chemicals industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Materials dividend stocks may want to explore other Materials stocks or use the stock screener to filter by dividend yield.
BCPC Momentum and Technical Analysis Profile
BALCHEM CORP (BCPC) has a momentum factor score of 51/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 27/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 27/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.
BCPC vs Competitors — Materials Sector Ranking and Peer Comparison
Comparing BCPC against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full BCPC vs S&P 500 (SPY) comparison to assess how BALCHEM CORP stacks up against the broader market across all factor dimensions.
BCPC Next Earnings Date
No upcoming earnings date has been announced for BALCHEM CORP (BCPC) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy BCPC? — Investment Thesis Summary
BALCHEM CORP presents a balanced picture with arguments on both sides. Low volatility (stability score 88/100) reduces downside risk.
In summary, BALCHEM CORP (BCPC) earns a Hold rating with a composite score of 50.2/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on BCPC stock.
We'll email you when stocks you follow change their composite rating.
Institutional Research Dossier
BALCHEM CORP (BCPC) Deep Dive Analysis
Published on March 24, 2026
Action RatingHold
Sections
Executive Summary
Balchem Corp. currently holds a 'Hold' rating, a reflection of its solid profitability and stability, offset by concerns regarding its capital allocation and growth prospects. While the company exhibits strong margins and returns compared to its sector, its valuation appears stretched, and its investment score suggests potential inefficiencies in capital deployment. The primary takeaway is that Balchem is a well-managed, profitable entity operating in niche markets, but its current price may not fully compensate investors for the risks associated with its growth trajectory and capital allocation strategies.
The company's robust financial performance, particularly its superior margins and returns on equity relative to the materials sector, provides a degree of downside protection. However, the 'Hold' rating acknowledges the potential for multiple compression given its premium valuation and the need for improved capital allocation to drive future growth. Investors should closely monitor Balchem's ability to sustain its margins, effectively deploy capital, and navigate competitive pressures within its diverse operating segments.
Business Strategy & Overview
Balchem Corporation operates as a specialty ingredients and products manufacturer, serving a diverse range of industries including nutrition, food, pharmaceuticals, animal health, and industrial applications. The company's business model revolves around developing and marketing performance-enhancing ingredients, often utilizing proprietary technologies like microencapsulation and chelation. These technologies allow Balchem to create differentiated products that command premium pricing and foster customer loyalty.
The company's strategic positioning is centered on providing value-added solutions to its customers. In the Human Nutrition & Health segment, Balchem offers ingredients that enhance the taste, texture, and nutritional profile of food and beverage products. The Animal Nutrition & Health segment focuses on improving animal health and productivity through specialized feed additives. The Specialty Products segment caters to niche markets such as healthcare sterilization and industrial fumigation, providing critical products and services.
Balchem's growth strategy involves a combination of organic expansion and strategic acquisitions. The company invests in research and development to innovate new products and improve existing formulations. Acquisitions are used to expand its product portfolio, enter new markets, and gain access to complementary technologies. This dual approach allows Balchem to maintain a competitive edge and capitalize on emerging trends in its target industries.
The company's industry context is characterized by increasing demand for specialized ingredients and products that address specific customer needs. In the food and beverage industry, there is a growing emphasis on healthier and more sustainable ingredients. In the animal health industry, there is a focus on improving animal welfare and productivity. In the healthcare industry, there is a need for effective sterilization solutions. Balchem is well-positioned to capitalize on these trends due to its diversified product portfolio and technological expertise.
Balchem's sales strategy relies on a mix of direct sales, independent distributors, and sales agents. This multi-channel approach allows the company to reach a wide range of customers in different geographic regions and industries. The company also provides technical support and customer service to ensure that its products are used effectively and that customers are satisfied.
Execution Benchmarks audit
Revenue Growth
YOY expansion rate
14.3%
Sector: 1.8%
+717% VS SCTR
Economic Moat Analysis
Balchem possesses a narrow economic moat, primarily derived from product differentiation and, to a lesser extent, switching costs. The company's proprietary technologies, such as microencapsulation and chelation, enable it to create specialized ingredients and products that offer unique performance benefits. This differentiation allows Balchem to command premium pricing and maintain a competitive advantage in its target markets.
The microencapsulation technology, for example, allows Balchem to protect sensitive ingredients from degradation and control their release, enhancing their effectiveness. This technology is particularly valuable in the food and beverage industry, where it can be used to improve the taste, texture, and nutritional profile of products. Similarly, the chelation technology enhances the absorption of nutrients in animal feed, improving animal health and productivity.
Switching costs also contribute to Balchem's narrow moat. Once customers have incorporated Balchem's ingredients into their products or processes, they may be reluctant to switch to alternative suppliers due to the potential for disruption and the need to re-validate their formulations. This is particularly true in regulated industries such as pharmaceuticals and animal health, where switching suppliers can be a lengthy and costly process.
However, Balchem's moat is not wide due to the presence of competitors and the potential for technological disruption. While Balchem has a strong track record of innovation, other companies are also investing in research and development to create new and improved ingredients and products. Additionally, the company's reliance on specific technologies makes it vulnerable to disruption from alternative technologies that may offer superior performance or lower costs.
Furthermore, the company's moat varies across its different operating segments. The Specialty Products segment, which includes ethylene oxide sterilization products, may have a stronger moat due to regulatory barriers and the critical nature of these products. In contrast, the Human Nutrition & Health segment may have a weaker moat due to the greater availability of alternative ingredients and the lower switching costs.
Ultimately, Balchem's narrow moat provides a degree of competitive advantage, but it is not insurmountable. The company must continue to invest in innovation and maintain strong customer relationships to defend its market position and sustain its profitability.
Financial Health & Profitability
Balchem's financial health is generally strong, characterized by consistent revenue growth, healthy margins, and a solid balance sheet. The company has demonstrated a track record of revenue growth, with TTM revenue reaching $1.04 billion, a 14.3% increase compared to the sector average of 1.5%. This growth has been driven by a combination of organic expansion and strategic acquisitions.
The company's profitability is also impressive, with a gross margin of 35.7%, an operating margin of 20.2%, and a net margin of 14.7%. These margins are significantly higher than the sector averages, indicating Balchem's ability to command premium pricing and manage its costs effectively. The company's ROE of 11.9% is also substantially higher than the sector average of 2.7%, reflecting its efficient use of equity capital.
Balchem's balance sheet is relatively conservative, with a current ratio of 2.07, indicating ample liquidity. The company's debt-to-equity ratio of 34.00 is slightly below the sector average of 40.00, suggesting a moderate level of leverage. The company's cash balance of $65.09 million provides a cushion for future investments and acquisitions.
Analyzing the quarterly financial history reveals a consistent trend of revenue and earnings growth. Revenue has increased steadily over the past several quarters, driven by strong performance across all three operating segments. Net income has also increased, reflecting the company's ability to maintain its margins and control its expenses. The gross margin has remained relatively stable, while the operating margin has shown some fluctuations due to changes in operating expenses.
However, the absence of free cash flow data in the provided information is a concern. Free cash flow is a critical metric for assessing a company's ability to generate cash and fund its growth initiatives. Without this data, it is difficult to fully evaluate Balchem's financial health and its ability to sustain its dividend payments and share repurchases.
Overall, Balchem's financial health is sound, but the lack of free cash flow data warrants further investigation. Investors should closely monitor the company's cash flow generation and its ability to maintain its margins and returns in the face of increasing competition and economic uncertainty.
Valuation Assessment
Balchem's valuation appears stretched based on its current P/E and EV/EBITDA multiples. The company's P/E ratio of 33.8x is significantly higher than the sector average of 26.1x, suggesting that investors are paying a premium for its earnings. Similarly, its EV/EBITDA multiple of 6.2x is higher than the sector average of 5.2x, indicating that the company is also more expensive on an enterprise value basis.
The premium valuation may be justified by Balchem's superior growth and profitability compared to its sector peers. The company's revenue growth of 14.3% is significantly higher than the sector average of 1.5%, and its margins and returns are also substantially higher. However, the question is whether this premium is sustainable and whether the company can continue to deliver above-average growth and profitability.
The lack of free cash flow data makes it difficult to assess the company's valuation using a discounted cash flow (DCF) analysis. A DCF analysis would provide a more comprehensive assessment of the company's intrinsic value by considering its future cash flows and its cost of capital. Without this data, investors must rely on relative valuation metrics such as P/E and EV/EBITDA, which may not fully capture the company's value.
Considering Balchem's historical valuation, its current multiples are at the higher end of its historical range. This suggests that the stock may be overvalued and that there is limited upside potential. However, it is important to note that the company's valuation has fluctuated significantly over time, and it is possible that its current multiples are justified by its improved financial performance and growth prospects.
Compared to its peers, Balchem's valuation is also relatively high. Other specialty chemicals companies with similar growth and profitability profiles trade at lower multiples. This suggests that Balchem may be overvalued relative to its peers and that there is a risk of multiple compression.
Overall, Balchem's valuation appears stretched, and investors should exercise caution before investing in the stock. The company's superior growth and profitability may justify a premium valuation, but the risk of multiple compression is significant. Investors should closely monitor the company's financial performance and its ability to sustain its growth and profitability in the face of increasing competition and economic uncertainty.
Risk & Uncertainty
Balchem faces several specific risks that could negatively impact its business and financial performance. One significant risk is raw material price volatility. The company relies on various raw materials, including ethylene oxide and propylene oxide, whose prices can fluctuate significantly due to supply and demand imbalances, geopolitical events, and other factors. Increases in raw material prices could erode Balchem's margins and reduce its profitability.
Another risk is competition. Balchem operates in competitive markets, and it faces competition from both large, diversified chemical companies and smaller, specialized ingredient manufacturers. Increased competition could lead to price erosion, reduced market share, and lower profitability. The company must continue to innovate and differentiate its products to maintain its competitive advantage.
A third risk is regulatory compliance. Balchem is subject to various environmental, health, and safety regulations in the countries where it operates. Changes in these regulations could increase the company's compliance costs and limit its ability to operate its facilities. The company must invest in compliance programs and maintain strong relationships with regulatory agencies to mitigate this risk.
A fourth risk is customer concentration. While Balchem serves a diverse range of customers, a significant portion of its revenue is derived from a small number of large customers. The loss of one or more of these customers could have a material adverse effect on the company's financial performance. The company must diversify its customer base and maintain strong relationships with its key customers to mitigate this risk.
Finally, the company's acquisition strategy also poses a risk. Balchem has grown through acquisitions, and it may continue to pursue acquisitions in the future. However, acquisitions can be risky, and there is no guarantee that the company will be able to successfully integrate acquired businesses or achieve the expected synergies. Poorly executed acquisitions could negatively impact the company's financial performance and its stock price.
Bulls Say / Bears Say
The Bull Case
BULL VIEWBalchem's specialized ingredient technologies, like microencapsulation, provide a sustainable competitive advantage, allowing for premium pricing and consistent profitability.
BULL VIEWThe company's diversified end markets, spanning nutrition, animal health, and specialty products, mitigate risk and provide resilience against economic downturns in any single sector.
BULL VIEWBalchem's strong balance sheet and consistent cash flow generation enable continued investment in R&D and strategic acquisitions, fueling future growth and market share gains.
The Bear Case
BEAR VIEWBalchem's high valuation leaves little room for error, and any slowdown in growth or margin compression could lead to significant multiple contraction.
BEAR VIEWThe company's reliance on specific technologies makes it vulnerable to disruption from alternative solutions or the emergence of new competitors with superior offerings.
BEAR VIEWThe lack of reported free cash flow raises concerns about the company's ability to fund its growth initiatives and maintain its dividend payments without increasing debt.
About the Author
Marques Blank
Founder & Chief Investment Officer, Blank Capital
Marques brings 15 years of institutional finance and investing experience, having overseen financial planning for a $1.6B defense business unit. He developed the proprietary 6-factor quantitative model used to score BCPC and 4,400+ other equities.
BALCHEM CORP exhibits a 273% valuation premium relative to institutional benchmarks. This represents a potential valuation overextension based on current multiples.
Return on Assets
Efficiency of asset utilization
8.9%
Sector: 0.6%
Gross Margin
Pricing power and cost efficiency
35.7%
Sector: 29.8%
Operating Margin
Core business profitability
20.2%
Sector: 6.0%
Net Margin
Bottom-line profitability
14.7%
Sector: 3.0%
Factor Methodology
The Quality factor evaluates the persistence and magnitude of cash flows. Companies with scores >70 exhibit superior competitive moats and financial resilience through economic cycles.
